Drugs / AZD8165
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01150812 | Jun → Aug 2010 | — | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8165 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01150812 ↗ |
| Modality | Small molecule | — CHEMBL3786896 ↗ |
| Route | Oral | “Oral suspension, 2 mg/mL and 20 mg/mL, single doses” NCT01150812 ↗ |